RIGL (RIGL) Stock Analysis
Verdict: BUY
Commercial oncology revenue expansion and positive cash flow derisk valuation, but high earnings lumpiness remains the key swing factor.
Investment score: 71/100
Rigel Pharmaceuticals demonstrates rare biotech profitability with 91.4% gross margins, 31.5% operating margins, and $75.7M FCF. Supported by three FDA-approved commercial drugs and an EV/EBITDA of 8.70x, the model identifies RIGL as an undervalued commercial growth play with consensus upside toward $67.00.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| IMMX | -14.16 | 3.47 | 0.00 | -11.26 | — | 0.00 |
| OLMA | -4.77 | 2.45 | 0.00 | -4.09 | — | 0.00 |
| CADL | -8.04 | 6.66 | 0.00 | -8.18 | — | 0.00 |
| ARDX | -15.22 | 5.72 | 1.88 | -42.37 | — | -0.12 |
| GERN | -13.17 | 4.03 | 4.12 | -21.60 | — | -0.34 |